What is claimed is:

1. A compound selected from the group consisting of (a) an isolindoline of the for-1

2 mula:

3

9

14

16

17

18

$$\begin{array}{c|c}
O & O & H \\
C & N & Y \\
X & R^2 & OH
\end{array}$$

4 wherein: the carbon atoms designated * constitute centers of chirality; 5 X is -C(O)- or $-CH_2$ -; 6 R¹ is alkyl of 1 to 8 carbon atoms or -NHR³; 7

R² is hydrogen, alkyl of 1 to 8 carbon atoms, or halogeno; and 8

R³ is hydrogen,

alkyl of 1 to 8 carbon atoms, unsubstituted or substituted with alkoxy of 1 to 10 8 carbon atoms, halo, amino, or alkylamino of 1 to 4 carbon atoms, 11 cycloalkyl of 3 to 18 carbon atoms, 12

13

phenyl, unsubstituted or substituted with alkyl of 1 to 8 carbon atoms, alkoxy of 1 to 8 carbon atoms, halo, amino, or alkylamino of 1 to 4 carbon atoms, 15

benzyl, unsubstituted or substituted with alkyl of 1 to 8 carbon atoms, alkoxy of 1 to 8 carbon atoms, halo, amino, or alkylamino of 1 to 4 carbon atoms, or

-COR⁴ in which 19

R⁴ is hydrogen, 20

1		alkyl of 1 to 8 carbon atoms, unsubstituted or substituted with
2		alkoxy of 1 to 8 carbon atoms, halo, amino, or alkylamino of 1
3		to 4 carbon atoms,
4		cycloalkyl of 3 to 18 carbon atoms,
5		phenyl, unsubstituted or substituted with alkyl of 1 to 8 carbor
6		atoms, alkoxy of 1 to 8 carbon atoms, halo, amino, or alkyl
7		amino of 1 to 4 carbon atoms, or
8		benzyl, unsubstituted or substituted with alkyl of 1 to 8 carbon
9		atoms, alkoxy of 1 to 8 carbon atoms, halo, amino, or alkyl
10		amino of 1 to 4 carbon atoms,
11	and	

- 12 (b) the acid addition salts of said isoindoline which are susceptible of protonation.
- 2. A compound according to Claim 1 in which in said isoindoline derivative R² is
 hydrogen, methyl, or fluoro.
- 15 3. A compound according to Claim 2 in which R² is hydrogen.
- 4. A compound according to Claim 3 in which said isoindoline derivative R¹ is
 amino.
- 18 5. A compound according to Claim 4 in which said isoindoline derivative X is -C(O).
- 19 6 A compound according to Claim 4 in which said isoindoline derivative X is -CH₂-.
- 7. A compound according to Claim 3 in which said isoindoline derivative R¹ is methyl.
- 22 8. A compound according to Claim 2 in which said isoindoline derivative X is -C(O)-.
- 23 9. A compound according to Claim 2 in which said isoindoline derivative X is -CH₂-.
- 10. The compound according to Claim 1 which is 2-(2,6-dioxo-3-hydroxypiperidin-5-yl)-4-aminoisoindoline-1,3-dione.
- 26 11. The compound according to Claim 1 which is 2-(2,6-dioxo-3-hydroxypiperidin-5-yl)-4-aminoisoindolin-1-one.

- 1 12. The compound according to Claim 1 which is 2-(2,6-dioxo-3-hydroxypiperidin-5-
- 2 yl)-4-methylisoindoline-1,3-dione.
- 3 13. The compound according to Claim 1 which is 2-(2,6-dioxo-3-hydroxypiperidin-5-
- 4 yl)-4-methylisoindolin-1-one.
- 5 14. A method of reducing or inhibiting undesirable levels of TNF α in a mammal
- 6 which comprises administering thereto an effective amount of a compound
- 7 according to Claim 1.
- 8 15. A method of treating in a mammal a disease selected from the group consisting
- 9 of inflammatory disease, autoimmune disease, arthritis, rheumatoid arthritis,
- inflammatory bowel disease, Crohn's disease, aphthous ulcers, cachexia, graft
- versus host disease, asthma, adult respiratory distress syndrome, and acquired
- immune deficiency syndrome, which comprises administering thereto an effective
- amount of a compound according to Claim 1.
- 14 16. A method of treating cancer in a mammal which comprises administering
- 15 thereto an effective amount of a compound according to Claim 1.
- 16 17. A method of treating undesirable angiogenesis in a mammal which comprises
- administering thereto an effective amount of a compound according to Claim 1.
- 18. A pharmaceutical composition comprising (i) a quantity of a compound accord-
- ing to Claim 1 that upon administration in a single or multiple dose regimen is
- 20 pharmaceutically effective and (ii) a pharmaceutically acceptable carrier therefor.